Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Shimura

Showing results (241-250 of 244) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 244 results.
ESMO Open|September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16H Yasui, Y Okita, M Nakamura, et al.
The Japanese Journal of Antibiotics|September 1, 1981
[Clinical evaluation of pivmecillinam in the maintenance therapy of chronic urinary tract infection (author's transl)]T Tamaya, T Tsurusaki, H Kusanishi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancerT Sakakida, T Masuishi, M Asayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 25

Showing results (241-250 of 244) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 244 results.
ESMO Open|September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16H Yasui, Y Okita, M Nakamura, et al.
The Japanese Journal of Antibiotics|September 1, 1981
[Clinical evaluation of pivmecillinam in the maintenance therapy of chronic urinary tract infection (author's transl)]T Tamaya, T Tsurusaki, H Kusanishi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancerT Sakakida, T Masuishi, M Asayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 25